Current Filters

Showing 11 - 20 results of 3489

Infliximab (Inflectra) (Last Updated: Jun 17, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Inflectra
Manufacturer:
Hospira Healthcare Corporation
Submission Type:
Initial
Indications:

Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis

Infliximab (Remsima) (Last Updated: May 30, 2014)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Remsima
Manufacturer:
Fresenius Kabi Canada
Submission Type:
Initial
Indications:

Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis

Ingenol mebutate (Picato) (Last Updated: May 26, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Picato
Manufacturer:
Leo Pharma Inc.
Submission Type:
Request For Advice
Indications:

Actinic keratosis

Darunavir/cobicistat (Prezcobix) (Last Updated: May 22, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Prezcobix
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

HIV Infection

Tofacitinib (Xeljanz) (Last Updated: May 5, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Xeljanz
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Arthritis, Rheumatoid

Ivacaftor (Kalydeco) (Last Updated: May 1, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Kalydeco
Manufacturer:
Vertex Pharmaceuticals Canada
Submission Type:
Initial
Indications:

Cystic Fibrosis (CFTR gating mutations)

Darunavir / cobicistat (TBC) (Last Updated: Apr 4, 2014)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
TBC
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

HIV infection

Eltrombopag (Revolade) (Last Updated: Mar 31, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Revolade
Manufacturer:
GlaxoSmithKline
Submission Type:
Initial
Indications:

Thrombocytopenia associated with chronic hepatitis c infection

Everolimus (Afinitor) (Last Updated: Mar 19, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Afinitor
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Subependymal giant cell astrocytoma associated with tuberous sclerosis complex

Icatibant (Firazyr) (Last Updated: Mar 4, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Firazyr
Manufacturer:
Shire Human Genetic Therapies (Canada) Inc.
Submission Type:
Initial
Indications:

Angioedema, hereditary

Download results as CSV